Search results for "Peripheral T-cell lymphoma not otherwise specified"

showing 2 items of 2 documents

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified

2014

Peripheral T-cell lymphomas not otherwise specified (PTCLs/NOS) are rare and aggressive tumours whose molecular pathogenesis and diagnosis are still challenging. The microRNA (miRNA) profile of 23 PTCLs/NOS was generated and compared with that of normal T-lymphocytes (CD4+, CD8+, naive, activated). The differentially expressed miRNA signature was compared with the gene expression profile (GEP) of the same neoplasms. The obtained gene patterns were tested in an independent cohort of PTCLs/NOS. The miRNA profile of PTCLs/NOS then was compared with that of 10 angioimmunoblastic T-cell lymphomas (AITLs), 6 anaplastic large-cell lymphomas (ALCLs)/ALK+ and 6 ALCLs/ALK - . Differentially expressed…

Female; Gene Expression Profiling; Humans; Lymphoma T-Cell Peripheral; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; RNA Neoplasm; Gene Expression Regulation Neoplastic; Oncology; Hematology; Medicine (all)Malemedicine.medical_specialtyPathologyPeripheral T-cell lymphoma not otherwise specifiedBiologyhemic and lymphatic diseasesInternal medicinemicroRNAmedicineHumansRNA NeoplasmOligonucleotide Array Sequence AnalysisRegulation of gene expressionHematologymicroRNA; PTCLs/NOS; GEPOligonucleotide Array Sequence AnalysiGene Expression ProfilingMedicine (all)Not Otherwise SpecifiedLymphoma T-Cell PeripheralMicroRNAHematologymedicine.diseaseGEPLymphomaGene expression profilingGene Expression Regulation NeoplasticMicroRNAsOncologyPTCLs/NOSOriginal ArticleFemaleCD8Human
researchProduct

Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and…

2020

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non-Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old …

Oncologyperipheral t-cell lymphomamedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryPeripheral T-cell lymphoma not otherwise specifiedCase ReportSettore MED/08 - Anatomia Patologicarituximab.03 medical and health sciences0302 clinical medicinerituximabimmune system diseasesInternal medicinehemic and lymphatic diseasesMedicineb-cell antigens; cd20; cd79a; peripheral t-cell lymphoma; rituximabCD20cd79aperipheral T-cell lymphomaB-cell antigenCD20lcsh:R5-920Chemotherapybiologybusiness.industryNot Otherwise Specifiedcd20CD79amedicine.diseaseCD79APeripheral T-cell lymphomaLymphomab-cell antigens030220 oncology & carcinogenesisbiology.proteinRituximablcsh:Medicine (General)business030215 immunologymedicine.drug
researchProduct